SLC5A2 and kidney disorder: Empagliflozin, a recently published therapeutic drug targeting proximal tubules, is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) and significantly reduced the progression of kidney disease in type 2 diabetic patients [49].